City of Hope Medical Center: Brain Neoplasms trials

The registry lists 13 Brain Neoplasms studies with City of Hope Medical Center as lead sponsor. 3 are open to participants now and 0 have results posted.

Early Phase 1 1Phase 1 8Phase 2 2Phase 4 1No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A PET Imaging Agent (64Cu-DOTA-Pembrolizumab) for Determining Treatment Response Among Patients With Stage IV Non-small Cell Lung Cancer Receiving PembrolizumabRecruitingNCT07619599Phase 1
• An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain MetastasisRecruitingNCT05376878Phase 4
• CAR T Cells After Lymphodepletion for the Treatment of IL13Rα2 Positive Recurrent or Refractory Brain Tumors in ChildrenRecruitingNCT04510051Phase 1
• Cemiplimab for the Treatment of Untreated Brain Metastases From PD-L1 >= 50% Non-Small Cell Lung CancerWithdrawnNCT05840770Phase 2
• Low Dose Versus Standard Dose Dexamethasone for Reduction of Swelling in Patients with Primary or Metastatic Brain TumorsActive, not recruitingNCT05139043Phase 2
• HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal MetastasesActive, not recruitingNCT03696030Phase 1
• Neuropharmacokinetics of Eribulin Mesylate in Treating Patients With Primary or Metastatic Brain TumorsCompletedNCT02338037Early Phase 1
• Feasibility of Intraoperative Optical Imaging and Spectroscopy in Brain TumorsCompletedNCT01627535Not applicable
• Bafetinib in Treating Patients With Recurrent High-Grade Glioma or Brain MetastasesCompletedNCT01234740Phase 1
• A Pilot Feasibility Study of Oral 5-Fluorocytosine and Genetically-Modified Neural Stem Cells Expressing E.Coli Cytosine Deaminase for Treatment of Recurrent High Grade GliomasCompletedNCT01172964Phase 1
• Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2CompletedNCT01082926Phase 1
• A Feasibility, Dose-Escalation Study Using Intracerebral Microdialysis to Assess the Neuropharmacodynamics of Temsirolimus in Patients With Primary or Metastatic Brain TumorsCompletedNCT00784914Phase 1
• Cellular Adoptive Immunotherapy Using Genetically Modified T-Lymphocytes in Treating Patients With Recurrent or Refractory High-Grade Malignant GliomaCompletedNCT00730613Phase 1